Research report

The transporter and permeability interactions of asymmetric dimethylarginine (ADMA) and L-arginine with the human blood–brain barrier in vitro

Christopher P. Watsona, Evangelos Pazarentzosb, Mehmet Fidanboylua, Beatriz Padillaa, Rachel Browna, Sarah A. Thomasa,∗

†King’s College London, Institute of Pharmaceutical Science, Waterloo, London, UK
<b>Imperial College London, Experimental Medicine and Toxicology Section, Division of Experimental Medicine, London, UK

A R T I C L E   I N F O

Article history:
Received 25 November 2015
Accepted 14 July 2016
Available online 16 July 2016

Keywords:
Cationic amino acid transporter 1
Nitric oxide
Guanosine triphosphatases (GTPases)
Cerebral microvasculature

A B S T R A C T

The blood–brain barrier (BBB) is a biological firewall that carefully regulates the cerebral microenvironment by acting as a physical, metabolic and transport barrier. This selectively permeable interface was modelled using the immortalised human cerebral microvascular endothelial cell line (hCMEC/D3) to investigate interactions with the cationic amino acid (CAA) L-arginine, the precursor for nitric oxide (NO), and with asymmetric dimethylarginine (ADMA), an endogenously derived analogue of L-arginine that potently inhibits NO production. The transport mechanisms utilised by L-arginine are known but they are not fully understood for ADMA, particularly at the BBB. This is of clinical significance giving the emerging role of ADMA in many brain and cerebrovascular diseases and its potential as a therapeutic target. We discovered that high concentrations of ADMA could induce endothelial dysfunction in the hCMEC/D3s BBB permeability model, leading to an increase in paracellular permeability to the paracellular marker FITC-dextran (40 kDa). We also investigated interactions of ADMA with a variety of transport mechanisms, comparing the data with L-arginine interactions. Both molecules are able to utilise the CAA transport system y+L and β0+, have an important physiological role in ADMA transport at the BBB. These data are not only important with regards to the brain, but apply to other microvascular endothelia where ADMA is a major area of investigation.

© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

1. Introduction

ADMA is an endogenously derived analogue of the CAA, L-arginine, and is produced during routine proteolysis of methylated arginine residues on proteins by a group of enzymes called protein-arginine methyltransferases (PRMTs) (Palm et al., 2007). Whereas L-arginine is a substrate for nitric oxide synthases (NOS) which catalyse the oxidation of L-arginine to L-citrulline and nitric oxide (NO) (using NADPH and O2 as co-substrates), ADMA acts as a potent inhibitor of NO production and inhibits all NOS isoforms by competing with L-arginine for the NOS binding site (Vallance et al., 1992; Leiper and Vallance, 1999; Tran et al., 2003; Siroen et al., 2006; Kittel and Maas, 2014).

Because of its potency as an inhibitor of NO, ADMA has been implicated in a wide variety of pathophysiological conditions throughout the body including hypercholesterolemia, hyperhomocysteinemia and hypertriglyceridemia (Boger, 1998; Lundman et al., 2001; Sydow et al., 2003); a host of cardiovascular conditions (Boger, 2003, 2004; Perticone et al., 2005); neuroinflammatory and neurodegenerative diseases including Alzheimer’s disease (Selley, 2003; Arlt et al., 2008); cerebrovascular diseases such as stroke (Yoo and Lee, 2001; Brous et al., 2009); microangiopathy-related cerebral damage (Notsu et al., 2009), and recently, intrauterine foetal growth restriction (Laskowska et al., 2014).

Given these disease implications, it is somewhat surprising that the basic cellular transport mechanisms of ADMA remain understudied. The main reason is the structural similarity of ADMA to L-arginine which catalyse the oxidation of L-arginine to L-citrulline and nitric

Abbreviations: ADMA, asymmetric dimethylarginine; BBB, blood-brain barrier; CAA, cationic amino acids; CAT-1, cationic amino acid transporter 1; DDAH, N2, N2′-dimethylarginine dimethylaminohydrolase; GTPases, guanosine triphosphatases; IFN-γ, interferon gamma; LAT, large neutral amino acid transporters; L-NIO, N-nitro-o-phenylendiamine; MATE1, multidrug and toxic exclusion protein 1; NO, nitric oxide; NOS, nitric oxide synthase; OCT, organic cation transporter; OSPC, octanol-iminoethyl-L-ornithine; MATE1, multidrug and toxin exclusion protein 1; NO, nitric oxide (NO) (using NADPH and O2 as co-substrates), ADMA acts as a

* Corresponding author.
E-mail address: sarah.thomas@kcl.ac.uk (S.A. Thomas).

http://dx.doi.org/10.1016/j.brainres.2016.07.026
0006-8993/© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
arginine, suggesting that both molecules share transport mechanisms, although data directly looking at ADMA membrane transport in vascular endothelial cells is lacking. Recent work by Strobel et al. showed that ADMA is able to utilise CAT2 (2A and 2B), organic cation transporter 2 (OCT2) and multidrug and toxin exclusion protein 1 (MATE1), albeit in a HEK293 cell model over-expressing these transporters and not vascular endothelial cells. They showed that the transport kinetics of CAT2A, CAT2B, and OCT2 indicate a low affinity, high capacity transport for ADMA (Strobel et al., 2013). Interestingly, a study by Ohtsuki et al. (2013) could not detect the expression of MATE1 and OCT2 membrane proteins in hCMEC/D3 cells. In addition, the transport of ADMA at the blood-brain barrier (BBB) has yet to be investigated despite the emerging role of the molecule in brain and cerebrovascular pathologies and the importance of the BBB as a dynamic interface between the brain and blood (Abbott et al., 2006). The transport mechanisms for L-arginine have been described at the bovine BBB: the principle L-arginine transporters here are CAT1, CAT2B and CAT3, which are all members of system y+ (O’kane et al., 2006). Interestingly, other data have implicated the system y+ large neutral amino acid transporters (y+LAT1) y+LAT2 and y+LAT2 in human in vitro BBB models (Carl et al., 2010).

One of the aims of this study was to test the hypothesis that ADMA has a similar transport profile to L-arginine in human brain endothelial cells. A major issue with BBB research (as with most other fields) is that the wide variety of models in use can make it difficult to relate and compare data, particularly between species. For example, much of the CAA transport work has utilised single cloned transporters expressed in Xenopus laevis oocytes and this is unlikely to give an accurate indication of the situation in mammalian systems where multiple transporters are present.

The hCMEC/D3 cell line is a commercially available, easily grown and transferable population of human microvascular CEC that stably maintains a normal BBB phenotype. These include expression of tight junction proteins, polarized expression of multiple ABC/SLC transporters and restrictive permeability. It has been used in over 100 different published studies of the BBB (Weksl er et al., 2013).

We thus compared the transport of ADMA and L-arginine in an accumulation model format using this well-established hCMEC/D3 human BBB model (Watson et al., 2012).

We also investigated the association between ADMA concentration and endothelial dysfunction. Such associations have been made in a variety of pathological conditions including chronic heart failure, renal failure, and a variety of diabetic complications such as renin-angiotensin system mediated diabetic retinopathy (Rog er et al., 1998; Leiper et al., 2007, Chen et al., 2009; Chen et al., 2011). ADMA and its metabolising enzyme, Nε, Nε-dimethylarginine dimethylaminohydrolase (DDAH), have also recently been implicated as regulators of pulmonary endothelial barrier function through the modulation of small guanosine triphosphatases (GTPases). This has been demonstrated in both in vitro and in vivo with mouse models (Wojciak-Stothard et al., 2007, 2009). ADMA has also been heavily implicated in the production of reactive oxygen species (ROS) via uncoupling of endothelial NOS, causing the enzyme to produce superoxides and not NO (Sydow and Munzel, 2003; Chen et al., 2011).

One of the hallmarks of endothelial dysfunction is an increase in leakiness via the paracellular route. Whereas the above-mentioned studies investigated the effects of ADMA on non-cerebral vasculature, no group has yet studied ADMA and BBB dysfunction. This is of particular importance because not only is BBB integrity paramount for maintaining homeostasis within the cerebral microenvironment, but ADMA has also been implicated in endothelial dysfunction in brain and cerebrovascular disorders such as ischemic stroke (Scherbakov et al., 2012).

Therefore, we investigated the effects of ADMA on the integrity of the human BBB in vitro using the hCMEC/D3 cell line in a paracellular permeability model format. Other in vitro studies have only investigated ADMA in cerebral endothelial dysfunction at high concentrations, so we decided to look at a range covering the physiological and pathophysiological concentrations of ADMA. We hypothesised that increased concentrations of ADMA would lead to increased BBB permeability, especially at concentrations in line with previous non-BBB studies, but did not rule out the possibility that lower concentrations may also induce permeability changes.

2. Results

2.1. Octanol-saline partition coefficient (OSPC) of [3H]L-arginine and [3H]ADMA

An OSPC was performed on all radiolabelled compounds to assess their relative lipophilicity which would give an indication of their potential to cross cell membranes by passive diffusion and accumulate in the cells. The mean OSPC values for [3H]-arginine (MW 174.2 g/mol) and [3H]ADMA (MW 202.25 g/mol) were 0.0015 ± 0.0002 and 0.0023 ± 0.0001 respectively (n = 3). These values are statistically significantly different from each other (p < 0.01). Our group previously performed OSPC analysis on [14C]sucrose (MW 342.3 g/mol; n = 3) obtaining a mean value of 0.0044 ± 0.00001, which was significantly lower when compared to [3H]-L-arginine and [3H]ADMA (both p < 0.001).

2.2. [3H]L-arginine and [3H]ADMA accumulation comparison

The values for [14C]sucrose and protein corrected [3H]-L-arginine and [3H]ADMA accumulation in the hCMEC/D3 cells are shown in Figs. 1 and 2, respectively. The accumulation of [3H]ADMA (38 nM) in the hCMEC/D3 cells increased in a time-dependent manner from a Vd of 13.58 ± 0.66 μl/mg protein at 1 min, to a Vd of 61.24 ± 2.92 μl/mg protein at 30 min. In a similar manner, the accumulation of [3H]arginine (7 nM) increased in a time-dependent manner from a Vd of 33.75 ± 1.70 μl/mg protein at 1 min, to a Vd of 106.79 ± 1.73 μl/mg protein at 30 min. At all time points, [3H]-arginine Vd values were significantly higher than those for [3H]ADMA (p < 0.001 at all time points).

2.3. Accumulation of [3H]L-arginine – role of CAA transporters

To assess the roles of CAA transporters on the transport and accumulation of [3H]-arginine in the hCMEC/D3s, 100 μM unlabelled L-arginine, 20 mM L-homoarginine and 100 μM L-leucine were added individually to the accumulation buffer alongside [3H]-arginine and [14C]sucrose, and compared to appropriate controls.

The control Vd values (μl/mg of protein) for [3H]-arginine were 33.75 at 1 min, 57.99 at 2.5 min, 79.84 at 5 min, 100.30 at 20 min and 106.79 at 30 min. The addition of 100 μM unlabelled L-arginine caused a marked decrease in the accumulation of [3H]-arginine (p < 0.001), with an average percentage decrease across the time points of 73% (Fig. 1A). Accumulation was almost completely inhibited (with an approximate decrease of 98% observed across all time points) with the addition of 20 mM L-homoarginine (p < 0.001). The addition of 100 μM L-leucine to the accumulation buffer caused no significant changes in [3H]-arginine accumulation.

To investigate the possible competitive effect of ADMA on the influx and accumulation of [3H]-arginine, 0.5 μM, 3 μM, and 500 μM unlabelled ADMA were added individually to the accumulation buffer. When 0.5 μM and 3 μM ADMA was added, there were no significant differences in accumulation when compared to

C.P. Watson et al. / Brain Research 1648 (2016) 232–242
However, an average decrease in [3H]L-arginine accumulation of 83% across the time points was seen with the addition of 500 μM ADMA (p < 0.001) when compared to controls (Fig. 1B).

2.4. Accumulation of [3H]ADMA – role of CAA transporters

To elucidate the transport mechanisms utilised by ADMA in the hCMEC/D3s, a series of accumulation experiments similar to those used for [3H]L-arginine were designed to assess the effects of self-inhibition, competitive inhibition and CAA transporters on the transport and resulting accumulation of [3H]ADMA and [14C]sucrose.

The control Vd values (μl/mg of protein) for [3H]ADMA were 13.58 at 1 min, 25.36 at 2.5 min, 41.32 at 5 min, 58.76 at 20 min and 61.24 at 30 min. To investigate self- and cross-inhibition of [3H]ADMA transport and accumulation, 0.5 μM, 3 μM and 500 μM unlabelled ADMA as well as 100 μM L-arginine were added individually to the accumulation buffer which also contained [3H]ADMA and [14C]sucrose. 0.5 μM ADMA caused a decrease in Vd while [3H]ADMA, but this failed to attain statistical significance. In contrast, 3 μM caused significant decreases in [3H]ADMA accumulation at 20 min and 30 min (p < 0.05, Fig. 2A). A decrease in [3H]ADMA accumulation of 87% was observed across all time points on the addition of 500 μM ADMA and 100 μM L-arginine were added individually to the accumulation buffer. *p < 0.05, ***p < 0.001. (B) To understand the roles CAA transporters played in the transport and subsequent accumulation of [3H]ADMA, the addition of known AA transporter interacting molecules was performed in an accumulation model using confluent hCMEC/D3s. * p < 0.05, ** p < 0.01. All [3H]ADMA data are corrected for protein content and [14C]sucrose (with [14C]sucrose corrected for protein only) and expressed as means ± SEM, n = 5 (A) or 4–6 (B) plates with 6 replicates per plate.

Fig. 1. Accumulation of [3H]L-arginine in hCMEC/D3 cells. (A) To understand the roles CAA transporters played in the transport and subsequent accumulation of [3H]L-arginine, self-inhibition and the addition of known AA transporter interacting molecules was performed in an accumulation model using confluent hCMEC/D3s.

Fig. 2. Accumulation of [3H]ADMA in hCMEC/D3 cells. (A) To investigate self and competitive inhibition on [3H]ADMA transport and accumulation, 0.5 μM, 3 μM and 500 μM unlabelled ADMA and 100 μM L-arginine were added individually to the accumulation buffer. *p < 0.05, ***p < 0.001. (B) To understand the roles CAA transporters played in the transport and subsequent accumulation of [3H]ADMA, the addition of known AA transporter interacting molecules was performed in an accumulation model using confluent hCMEC/D3s. *p < 0.05, **p < 0.01. All [3H] ADMA data are corrected for protein content and [14C]sucrose (with [14C]sucrose corrected for protein only) and expressed as means ± SEM, n = 5 (A) or 4–6 (B) plates with 6 replicates per plate.
2.5. Accumulation of \([^{14}C]\)sucrose

Sucrose was used throughout the transport assays as a marker for unspecific binding and extracellular space. There were no significant changes in the accumulation of \([^{14}C]\)sucrose from baseline values in any transport studies in this investigation (data not shown).

2.6. Expression of CAT-1 in hCMEC/D3 cells

Rabbit anti-human CAT-1 primary antibody was used with goat anti-rabbit HRP conjugated secondary antibody for WB detection of CAT-1 in the TGN lysed hCMEC/D3s and wt MCF7 whole cell lysates. The blot revealed expression of CAT-1 of the expected size of 60–70 kDa (Fig. 3A) according to the antibody manufacturer and previously published studies (Battisti et al., 2012; Mun et al., 2011; Diaz-Perez et al., 2012; Strobel et al., 2012).

CAT-1 expression was also observed with IF and subsequent confocal microscopy in the hCMEC/D3 cells (Fig. 3B) using rabbit anti-human CAT-1 primary antibody and goat anti-rabbit Alexa Fluor 488 conjugated secondary antibody. It showed typical membrane/cytoskeletal-like patterning (Closs et al., 2004).

2.7. Effects of ADMA on hCMEC/D3 permeability to 40 kDa FITC-dextran

To investigate the impact of ADMA on the integrity of the hCMEC/D3s, cells grown on transwell filters for 8–10 days were incubated with a range of ADMA concentrations for 24 hr before permeability assays with FITC-Dex were performed (Fig. 4A). The concentrations of ADMA used reflected the physiological (0.5 \(\mu\)M), pathophysiological (3 \(\mu\)M) human plasma ranges, as well as 10 \(\mu\)M and 100 \(\mu\)M (values used in published in vitro studies by other research groups). 500 \(\mu\)M was used as an extreme reference point.

There were no significant differences between the 0.5 \(\mu\)M, 3 \(\mu\)M and 10 \(\mu\)M ADMA treatments between each other or control cells (untreated) on the permeability of the hCMEC/D3 cells to FITC-Dex. However, the incubation of the cells with 100 \(\mu\)M ADMA saw a significant increase in the permeability to FITC-Dex when compared to controls (52% increase, \(p < 0.05\)) and 10 \(\mu\)M ADMA (53% increase, \(p < 0.05\)).

Incubation with 50 \(\mu\)M ADMA caused a significant increase in permeability when compared to the 0.5 \(\mu\)M, 3 \(\mu\)M, 10 \(\mu\)M ADMA treatments and controls (\(p < 0.01\) in all instances); 84% increase versus controls; 67% increase versus 0.5 \(\mu\)M ADMA; 73% increase when compared to 3 \(\mu\)M; and an 85% increase compared to 10 \(\mu\)M ADMA. There were no significant differences in permeability coefficients between 100 \(\mu\)M and 500 \(\mu\)M ADMA treatments.

2.8. Effects of L-NIO and TNF-\(\alpha\) plus IFN-\(\gamma\) on hCMEC/D3 permeability to 40 kDa FITC-dextran

The potent eNOS inhibitor L-NIO and the pro-inflammatory cytokines TNF-\(\alpha\) and IFN-\(\gamma\) were incubated with the hCMEC/D3s grown on transwell filter inserts, to investigate their effects on permeability to 40 kDa FITC-Dex.

When compared to controls, 5 \(\mu\)M L-NIO caused no significant changes in permeability (Fig. 4B). When incubated with 5 ng/ml TNF-\(\alpha\) and 5 ng/ml IFN-\(\gamma\), permeability of hCMEC/D3 cells to FITC-Dex significantly increased when compared to controls (\(p < 0.001\)) and L-NIO (\(p < 0.001\)). The percentage increases were 200% compared control and 204% compared to L-NIO.
2.9. Cytotoxicity of compounds used

No cytotoxic effects were detected using an MTT assay throughout the experiments, except in the 24-h incubations used in the transwell permeability experiments. Here the ADMA concentrations of 100 μM and 500 μM and 5 ng/ml TNF-α and 5 ng/ml IFN-γ caused significant reductions in cell viability (p < 0.05, p < 0.01 and p < 0.001 respectively for treatments, Fig. 5).

2.10. Generation of ROS

The effect of ADMA on the generation of ROS was assessed in the cells by measuring DHE fluorescence after 24 h (ADMA) or 30 min (H₂O₂) exposure, as described. DHE fluorescence indicates that exposure to ADMA did not increase ROS in these cells after a 24 h exposure at any of the doses tested (one way ANOVA, *p < 0.05).

3. Discussion

The idea that ADMA plays roles in endothelial dysfunction and...
in vitro and in vivo data from a variety of studies on different body regions. ADMA is also a ‘hot-topic’ of investigation in vascular biology research as it is a potent inhibitor of NO production (Teerlink et al., 2009). ADMA is therefore of acute interest to researchers investigating specialised vasculature such as the BBB, particularly given that NO appears to have functional and protective roles as well as deleterious effects depending on its source and the state of brain and cerebrovascular health (Thiel and Audus, 2001). Furthermore, ADMA has been implicated as not only a marker, but also a mediator of cerebral perfusion and cognitive impairment in microangiopathy-related cerebral damage (Kielstein and Kielstein, 2009, Notsu et al., 2009). In acute stroke, increased levels of ADMA have been observed in transient ischemic attacks and cardioembolic infarctions (Wanby et al., 2006; Scherbakov et al., 2012) and ADMA levels in human CSF are believed to be correlated with stroke severity (Brouns et al., 2009). ADMA has also been implicated as a mediator of cerebral vascular tone, by increasing arterial stiffness and decreasing cerebral blood flow independent of blood pressure (Kielstein et al., 2006). We investigated the effects of ADMA on the human BBB by using the hCMEC/D3 in vitro BBB model, attempting to shed light on the basic mechanisms expressed at this interface for ADMA.

We first determined the OSPC values for the molecules under investigation, giving us an indication of their lipophilicity and passive membrane penetration without the influence of transporters. The data indicated that both [3H]L-arginine and [3H]ADMA had high hydrophilicity, with [3H]L-arginine having statistically lower lipophilicity than [3H]ADMA. Both molecules had higher lipophilic characteristics than [14C]sucrose, which is used as an impermeant paracellular permeability and non-specific binding marker in BBB studies. Therefore without the influence of transporters, the intracellular accumulation of [3H]L-arginine and [3H]ADMA should be low, but in a range similar or higher than [14C] sucrose. Interestingly, [3H]arginine accumulation into hCMEC/D3 cells was higher than that achieved for [3H]ADMA suggesting the influence of transporters.

Our investigations into the interactions between ADMA and CAA transporters is novel with respect to the human BBB and has wider implications due to the ubiquitous expression of CAA transporters throughout the body. Little is known about ADMA transport in vitro, especially in human endothelial cell systems mainly due to the assumption that it uses system y+ transporters like L-arginine (Teerlink et al., 2009). The only exceptions are studies using human embryonic kidney epithelial cells stably overexpressing CAT1 and CAT2 (2A & 2B) (Strobel et al., 2012, 2013).

We showed that the accumulation of [3H]L-arginine (7nM) was decreased significantly with the addition of 100 μM L-arginine, which is representative of the normal adult L-arginine plasma concentration (Moller et al., 1979, 1983). This suggests transport competition for influx transport mechanisms. Further experiments with 20 mM L-homoarginine revealed that the influx mechanisms utilised was a member of system y+, with an almost complete halt of accumulation seen within 1 min (98% decrease) which persisted for the rest of the 30 min time period observed. L-homoarginine is known to competitively inhibit system y+ (White, 1985) and the concentration used here was based on that of a previous in vitro BBB study using bovine BMECs (O’kane et al., 2006). The impact of L-homoarginine here also dismisses the L-arginine transport roles of other CAA influx mechanisms such as system y+ L transporters in the transport of L-arginine at the human BBB (O’kane et al., 2006). The lack of inhibition of L-arginine transport upon addition of the NAA leucine at physiological concentrations also supported the finding that system y+ appears to be the physiologically relevant transport system used by L-arginine in these cells.

These data were not unexpected, as it has been well established that system y+ is the principle CAA transport system in mammals. Which CAT isoform is responsible remains undetermined, but as CAT-1 is well characterised at the BBB, it remains likely that this protein is involved. A recent study investigating ADMA transport showed that CAT2A, CAT2B, and OCT2 indicate a low affinity, high capacity transport for ADMA in a human kidney cell line overexpressing these transport proteins (Strobel et al., 2013), suggesting that these are also involved in BBB transport of ADMA. The expression of CAT-1 was confirmed in hCMEC/D3s cells through WB of whole cell lysates and through IF analysis showing a staining pattern that suggests typical membrane localization and corresponds with previous studies on CAT-1 activity (Closs et al., 2004) as previously demonstrated in pulmonary artery endothelial cells (McDonald et al., 1997; Zharikov et al., 2001). We are consequently the first to report expression of CAT-1 in hCMEC/D3 cells, although further research is needed to further confirm the membrane localization of CAT-1 in these cells.

The addition of 500 μM unlabelled ADMA significantly reduced accumulation of [3H]L-arginine. In one respect, this finding provides evidence that both molecules can interact with the same transport mechanisms for entry to the cells. On the other hand, although a marked decrease in accumulation was observed, the concentration of 500 μM ADMA is supraphysiological and is not likely to be reached in the body. Importantly, when physiological (0.5 μM) and pathophysiological (3 μM) concentrations of ADMA were used, no significant change in [3H]arginine accumulation was observed. A similar finding has been previously reported using human dermal microvascular endothelial cells where 2.5 μM and 10 μM ADMA did not significantly reduce L-arginine accumulation (Xiao et al., 2001).

When investigating the accumulation of [3H]ADMA, self-inhibition was time dependent. The addition of 500 μM ADMA produced a significant decrease at all time points (an average of 87%). Overall the self-inhibition data suggests the evidence of influx mechanisms. The fact that the concentration of [3H]ADMA used was more than 10 times less than the lowest concentration of added unlabelled ADMA and not greatly affected by the ADMA additions until later time points, suggests that the transporter being used has a low affinity for ADMA and requires a high concentration of unlabelled molecule to demonstrate influx action.

The results from the addition of 100 μM L-arginine show a slight decrease in accumulation at later time points, despite being at a concentration more than 2000 times greater than [3H]ADMA. [3H]ADMA accumulation was decreased with the addition of 20 mM L-homoarginine or the addition of the NAA leucine at the human physiological plasma concentration (Psychogios et al., 2011). This finding suggests that multiple influx transporters are at work and that influx transport systems separate from system y+ could also be transporting ADMA as system y+ is insensitive to leucine (Rotmann et al., 2007). The most likely candidates are y+ L and b0,+ proteins, which have affinities for both CAA and NAs in the presence of Na+ ions (O’kane et al., 2006; Rotmann et al., 2007). Both proteins have been demonstrated at mRNA level in hCMEC/D3s cells (Carl et al., 2010).

Based on all these data, we conclude that physiological and pathophysiological extracellular concentrations of ADMA do not compete significantly with L-arginine for entry to cerebral endothelial cells, and that ADMA may use additional transport mechanisms to enter the endothelial cell. To investigate the effects of ADMA on BBB permeability, we used an assay where hCMEC/D3 cells were grown to confluence on filters and were incubated for 24 h with a range of ADMA concentrations. The Pᵣ values obtained were similar to those published with 40–70 kDa FITC-Dextran for hCMEC/D3 cells (Weksker et al., 2005; Forster et al., 2008). At ADMA concentrations of
100 μM and 500 μM we observed increases in permeability to 40 kDa FITC-Dex when compared to untreated controls. These data are consistent with previous in vitro studies investigating ADMA and endothelial dysfunction. In one such study, Chen et al. (2011) used bovine retinal capillary endothelial cells in a permeability model, and incubated the cells with 100 μM ADMA for 24 h and observed an increase in permeability to the paracellular marker, 44 kDa horseradish peroxidase, and a reduced expression of tight junction protein, occludin. In a study by Wojciak-Stothard et al. (2009) porcine pulmonary artery endothelial cells were incubated with 100 μM ADMA for 24 h. They observed a significant increase in permeability compared to control cells (Wojciak-Stothard et al., 2009). Recently, these findings were echoed when ADMA increased the permeability of HUVECs grown on transwell filters to 40 kDa FITC-Dex and FITC-apolin-13 (MW 2053) in a dose-(25–200 μM ADMA) and time- (4, 8, 16 and 24 h) dependent manner (Wang et al., 2011).

Chen et al. (2011) showed that ADMA decreased bovine retinal endothelial cell proliferation in a dose-dependent manner, but did not link these effects as a possible explanation behind the observed increase in permeability. They suggested that ADMA induced ROS formation caused this endothelial dysfunction. Cerebrovasculature (BMECs) are extremely sensitive to oxidative stress due in part to their high expression of NADPH-oxidase, and this makes them vulnerable to increased concentrations of ROS (Uttara et al., 2009; Tripathy et al., 2010). Furthermore, ADMA inhibits the NADPH-oxidase pathway (Wang et al., 2011). In our study, 24 h incubations with 100 μM and 500 μM ADMA decreased hCMC/D3 cell viability, which may explain the permeability increase. However, the mechanism of this toxicity was not ADMA-induced superoxide formation, as demonstrated by the DHE assay. One way in which ADMA is believed to induce ROS formation is by eNOS uncoupling. With this in mind, we confirmed the expression of eNOS in our cells. The addition of the eNOS inhibitor L-NIO in our permeability experiments however, did not induce any significant permeability differences. Furthermore, DDAH enzymes metabolise ADMA and their activity is significantly decreased in conditions associated with increased oxidative stress such as hyperglycaemia and stroke (Lin et al., 2002; Tain and Baylis, 2007; see Sandoval and Witt (2008) and Chrissobolis et al. (2011) for review). We determined that DDAH-1 was expressed in the hCMC/D3 cells. Loss of DDAH-1 function in mice has been demonstrated to result in increased ADMA levels and endothelial dysfunction (Leiper et al., 2007). In relation to this, it has been demonstrated that mice aorta and cerebral arterioles over-expressing DDAH-1 are protected against ADMA-induced endothelial dysfunction using 100 μM ADMA (Dayoub et al., 2008).

Interestingly, Wojciak-Stothard et al. (2009) did not find any evidence of ADMA-induced cytotoxicity or changes in ROS in porcine pulmonary artery endothelial cells, but instead showed ADMA-induced cytoskeletal and adherens junction remodelling via modulation of the small GTPase Rac1. Small GTPases are implicated in the control of microvascular permeability; with Rac1 a major GTPase required for barrier stabilisation and maintenance (Spindler et al., 2010). Such cytoskeletal remodelling could induce cytotoxic effects explaining the reduced cell viability when the hCMC/D3s were incubated in high concentrations of ADMA, as discussed in the literature (Stupack and Cheresh, 2003).

TNF-α and IFN-γ increase BMEC permeability through disruption of cell-cell junctions (Minagar and Alexander, 2003) via activation of the transcription factor NFkB (Sandoval and Witt, 2008) and tyrosine-phosphorylation of adherens junction proteins by GTPases (Dejana et al., 2008). Their effect on hCMC/D3 permeability has also been demonstrated (Fletcher et al., 2011) with a similar increase in permeability to FITC-Dex noted (albeit using 70 kDa FITC-Dex). TNF-α and IFN-γ also lead to cytotoxicity in mouse vascular endothelial cells (Yamaoka et al., 2002). It appears likely that in our permeability model a combination of these effects were at work in that the hCMC/D3 junctional complexes were altered and cytotoxicity-induced apoptosis of the cells contributed to the increase in permeability.

The results of this study are twofold: firstly, they demonstrate that both L-arginine and ADMA appear to use system y+ influx mechanisms to enter hCMC/D3 BBB cells, as predicted due to their close structural similarity and chemical composition. They also demonstrate that this transporter could be CAT-1, the expression of which was confirmed in our human BBB model. Other influx systems such as systems y+L and b0,+ appear to have smaller roles in L-arginine transport, but may have more important roles for ADMA influx. Also physiological and pathophysiological extracellular concentrations of ADMA do not compete significantly with L-arginine transport into the BBB via system y+.

Secondly, the data from our study show that ADMA is able to increase paracellular permeability in human BBB cells. Although it was high ADMA concentrations that induced these permeability increases, that does not rule out the role of more clinically relevant concentrations in vivo, especially considering the sensitivity of intracellular DDAH enzymes to oxidative stress which can be induced from several sources during various disease states. ADMA has been demonstrated to induce endothelial dysfunction that could have serious implications in brain and cerebrovasculature pathologies, as well as on the integrity of the BBB itself. Consequently, ADMA is an interesting therapeutic target in neuro-inflammatory diseases. The fact that our BBB model expressed both eNOS and DDAH-1 makes it a good human in vitro BBB model to study the effects of ADMA and NO inhibition now and in future studies.

4. Experimental procedure

4.1. Materials

Tritium labelled L-arginine was purchased from American Radiolabelled Chemicals, Inc., MO, US and had a specific activity of 43 Ci/mmol. [14C]Sucrose was purchased from Moravek Biochemicals and had a specific activity of 4980 mCi/mmol. [3H]ADMA was custom radiolabelled by GE Healthcare, Amersham, UK and had a specific activity of 8 Ci/mmol. The Pierce bicinchoninic acid (BCA) protein assay, enhanced chemiluminescence (ECL) kit and all culture wear was purchased from Thermo Scientific, Thermo Scientific Nuncion, Loughborough, UK. The EGM-2MV BulletKit was purchased from Lonza, Wokingham, UK. Rat tail collagen type-I, penicillin-streptomycin, 0.25% Trypsin-EDTA, recombinant human TNF-α, recombinant human IFN-γ, Dulbecco’s modified Eagle’s medium without phenol red (DMEM) and Dulbecco’s Phosphate-Buffered Saline without calcium, magnesium and phenol red (DMEM) and Dulbecco’s Phosphate-Buffered Saline without calcium, magnesium and phenol red (DPBS) were all purchased from Gibco, Invitrogen, Paisley, UK. Foetal bovine serum (FBS) ‘gold’ was purchased from PAA the Cell Culture Company, Yeovil, Somerset, UK. Dimethyl sulfoxide (DMSO), phosphate buffered saline (PBS), 1 M HEPES, (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenylylterazolium bromide (MTT), unlabelled ADMA, unlabelled L-arginine, L-homoarginine, L-leucine, 40 kDa fluorescent isothiocyanate labelled dextran (FITC-Dex), Triton x-100, Hank’s balanced salt solution (HBSS), THG, lysis buffer components (Tris, NaCl, 10% glycerol, glycophosphate B, Tween 20 and NP-40), b-mercaptoethanol, ammonium persulfate (APS), N,N,N′N-tetramethylelendiamine (TEMED), 1-octanol, dihydroethidium (DHE), hydrocortisone, ascorbic acid, bFGF and Corning® Transwell® polyester membrane inserts (pore size 0.4 μm, membrane diameter 1.12 cm2) were all purchased from Sigma Aldrich Company Ltd., Poole, UK. N2-(1-Iminoethyl)-L-
ornithine (L-NIO) was manufactured by Cayman Chemicals and purchased from Cambridge Bioscience Ltd., Cambridge, UK. Proteoblock™ protease inhibitor cocktail and Page Ruler Prestained 10–170 kDa Protein Ladder were purchased from Fermentas Life Sciences, North Yorkshire, UK. 0.45 μm Immobilon-P polyvinylidene fluoride (PVDF) membrane was purchased from Millipore UK Ltd., Watford, UK. Human umbilical vein endothelial cell lysate was purchased from Santa Cruz Biotechnology, Inc., California, USA. Wild type MCF-7 whole cell lysate was kindly provided by Dr. Evangelos Pazarentzos of Imperial College London. Rabbit anti-human SLC7A1/CAT-1 polyclonal primary antibody, goat anti-human DDAH1 polyclonal primary antibody, mouse anti-human GAPDH monoclonal primary antibody, rabbit anti-goat HRP conjugated polyclonal secondary antibody, goat anti-rabbit HRP conjugated polyclonal secondary antibody and rabbit anti-mouse HRP conjugated polyclonal secondary antibody were all purchased from Abcam, Cambridge, UK. Rabbit anti-human NOS3/eNOS polyclonal primary antibody was purchased from BD Biosciences, San Diego, CA. 4,6-diamidino-2-phenylindole (DAPI) was purchased from Invitrogen, Paisley, UK. The hCMEC/D3 cell line was obtained from Professor Pierre O. Couraud (Institut Cochin, Université Paris Descartes, CNRS, Paris, France), Professor Babette Weksler (Weill Medical College of Cornell University, New York, NY, USA) and Dr Ignacio Romero (The Open University, Department of Life Sciences Walton Hall, Milton Keynes, UK). Human umbilical vein endothelial cell (HUVEC) whole cell lysate was purchased from Santa Cruz Biotechnology, Inc., California, USA. MCF7 whole cell lysate was a kind gift from Professor Stefan Grimm (Imperial College London).

4.2. Cell culture

The hCMEC/D3s were cultured using EGM-2MV BulletKit as described previously (Poller et al., 2008; Watson et al., 2012). All cells used in the experiments were between passage 25 and 35 and cells used in accumulation experiments were seeded at 2.5 x 10^4 cells/cm² on 0.1 mg/ml rat tail collagen type-I in HBSS.

Cells grown on transwell filters (Corning Transwell polyester membrane inserts, pore size 0.4 μm, membrane area 1.12 cm²) were seeded at a density of 120,000 cells per filter (determined using a haemocytometer). Filters were pre-coated for 2 h with 0.15 mg/ml rat tail collagen type-I in HBSS, before being washed once with DPBS at 37 °C and then incubated in permeability media before seeding (0.5 ml in donor well/filter insert and 1.5 ml in receiver wells). The permeability media is a reduced growth media which has been optimised by Professor Pierre Couraud's group (Institut Cochin, Université Paris Descartes, CNRS, Paris, France) and follows an established protocol allowing the cells to differentiate and form restrictive tight junctions, restricting paracellular permeability (Poller et al., 2008; Zougbede et al., 2011). Permeability media consisted of EBM-2 endothelial basal medium from the Clonetics™ EGM®–2MV BulletKit® with 5% FBS 'gold', 1% penicillin-streptomycin, 1.4 μM hydrocortisone, 5 μg/ml ascorbic acid, 10 mM HEPES and 1 mg/ml BFGF. The cells were also grown in an incubator with a saturated humidity at 37 °C in 5% CO2 and 95% fresh air. Media was changed every 2–3 days and cells used for experiments were between 8 and 10 days post-seeding.

Protein expression (BCA protein assay) and integrity of plasma membranes ([2H]ADMA) were monitored to confirm cell viability and used for correction factors (see details below).

4.3. Accumulation assays

For accumulation experiments, cells were grown to 100% confluence (reached at 4 days) in collagen coated 96 well plates and then left for a further 3 days until experiments (7 days after seeding). Medium was changed every 2–3 days. Experiments were performed on confluent monolayers of hCMEC/D3s, grown in the centre 60 wells of 96 well plates. Medium was aspirated from wells and replaced with a 200 μl aliquot of [3H]L-arginine or [3H]ADMA (7 nM or 38 nM, respectively) with [14C]sucrose (972 nM) as a correction for non-specific binding, with or without transporter interacting substrates/inhibitors in accumulation assay buffer (the composition of which has been published previously (Watson et al., 2012).

Cells were exposed to the [3H]test molecule/[14C]sucrose/buffer mix for five different time periods (1, 2.5, 5, 20 and 30 min) allowing assessment of radiolabelled molecule accumulation in the cells. The accumulation assays were performed on a temperature-controlled shaker (THERM0star, BMG labtech, Offenburg, Germany) at 37 °C and 120 rpm. Once each column of cells had been exposed for the correct amount of time, the wells were washed 3 times with ice-cold phosphate buffered saline (1 × PBS, Gibco, Invitrogen, UK) to stop transport processes and remove radiolabelled test molecules and buffer that had not accumulated in the cells. The cells were then lysed by adding 200 μl of 1% Triton X-100 (Sigma, UK) per well for 1 h at 37 °C to liberate any accumulated radiolabelled test molecule and solubilise the cell proteins. 100 μl of each well was then added to scintillation vial along with 4 ml scintillation fluid (Optiphase Hisafe 2, PerkinElmer, UK) and added and samples counted on a Tricarb 2900TR liquid scintillation counter (μl/mg). The remaining 100 μl in each well was used in a BCA™ protein assay, using bovine serum albumin as standards, and protein concentration measured spectrophotometrically on a Labsystems Multiscan reader with Ascent software. Total accumulation of [3H]test molecule in the cells was expressed as a volume of distribution (Vd). Vd is derived from the ratio of dpm/mg protein in the lysate to dpm/μl of the accumulation buffer. The Vd values for [3H]test molecule were corrected with the Vd values for [14C]sucrose which is a marker of non-specific binding and extracellular space.

4.4. Transporter inhibition assays

For [3H]L-arginine self-inhibition experiments, (which provide evidence of saturable mechanisms), 100 μM unlabelled L-arginine (a similar concentration to that present in human plasma) was added to the accumulation assay buffer along with the [3H]L-arginine and [14C]sucrose. In a separate experiments, the system y⁺ competitive substrate L-homoarginine (20 mM) and L-leucine (100 μM) were individually added to the accumulation assay buffer to investigate the role of system y⁺ and system y⁺L transporters on the transport of L-arginine.

In a separate series of accumulation experiments, the effects of a range of ADMA concentrations on [3H]L-arginine accumulation were also assessed. The physiological plasma concentration of 0.5 μM, the pathophysiological plasma concentration of 3 μM and the supraphysiological concentration of 500 μM (as an extreme reference point) were added separately to the accumulation buffer alongside [3H]L-arginine and [14C]sucrose (Teerlink et al., 2009).

For [3H]ADMA investigations, evidence for influx transport activity was assessed by self-inhibition studies using 0.5 μM, 3 μM and 500 μM unlabelled ADMA alongside [3H]ADMA and [14C]sucrose in the accumulation buffer. The influence of 100 μM unlabelled L-arginine, 100 μM L-leucine and 20 mM L-homoarginine were also separately investigated as with [3H]L-arginine.
4.5. L-arginine and ADMA Octanol-saline partition coefficient (OSPC)

To gain an indication of the lipophilicity of the study molecules, [1H]ADMA and [1H]L-arginine, an OSPC was performed using 0.037 MBq (1 μCi) of each molecule in 1 ml of saline as described previously (Sanderson et al., 2008). The OSPC of [14C]sucrose has been previously published by our group (Jeganathan et al., 2011). All OSPC measurements were performed in triplicate.

4.6. Permeability assay

To investigate the effect of ADMA on the integrity of the hCMEC/D3s, the paracellular permeability was investigated using permeability assays on confluent monolayers of hCMEC/D3s grown on 12 well plate transwell filter inserts.

At 8–10 days post seeding, the TEER of the monolayers on the filters was measured as described previously (Pataubendige et al., 2012), at least 4 h before the assay. Filters with TEERs less than the published hCMEC/D3 TEER values were not used for the permeability assays (Poller et al., 2008; Fletcher et al., 2011). Permeability media was replaced 24 h before the assay in both the insert (0.5 ml) and donor wells (1.5 ml) with fresh media containing one of the following concentrations: 0.5 μM ADMA, 3 μM ADMA, 1 μM ADMA, 100 μM ADMA or 500 μM ADMA. In a separate series of experiments, media was added to the cells for 24 h containing either L-NIO (a non-selective inhibitor of NO synthase) at a concentration of 5 μM (which is within the 3.9 μM Ki range of eNOS) (Rees et al., 1990), or 5 ng/ml recombinant human TNF-α with 5 ng/ml recombinant human IFN-γ, which have been shown to increase brain microvascular endothelial cell (BMEC) permeability (Minagar and Alexander, 2003; Sandalow and Witt, 2006; Dejana et al., 2008).

On the day of the experiment, this media was removed from the transwell filter insert and the donor well, and 1.5 ml pre-warmed (to 37 °C) DMEM (without phenol red) + 2% FBS was added to the wells of fresh 12 well plates. 40 kDa FITC-Dex was diluted to 2 μg/ml in a separate vial of DMEM + 2% FBS assay media and used as a BBB paracellular marker for the assay (Hoffmann et al., 2011) by adding 0.5 ml of it to the transwell filter insert only.

The filter was then moved into a new donor well on flat bottom 12 well plates (containing DMEM + 2% FBS) at 10-min intervals for 60 min. The fluorescence in each well of 12 well plate was then measured in a FlexStation® 3 Bench top Multi-Mode Microplate fluorescent plate reader at an excitation wavelength of 485 nm and emission wavelength of 530 nm, using SoftMax® Pro Microplate Data Acquisition & Analysis software.

Permeability of FITC-Dex during the assay was determined as permeability coefficients (Pe) which take into account the relation between the permeability of the monolayer and the permeability of empty filter pre-coated with rat tail collagen type 1 (without cells). These calculations are based on work by Dehouck et al. (1992) and Cecchelli et al. (1999), and have been used in subsequent hCMEC/D3 publications (Wekslers et al., 2005; Poller et al., 2008; Tai et al., 2009).

4.7. Detection of ROS formation

hMEC/D3 cells were plated into collagen-coated 24 well plates and grown for 3 days. Cells were treated with either media alone (control) or media containing ADMA (0.5, 3, 10, 100 and 500 μM) or 300 μM hydrogen peroxide (H₂O₂) as a positive control for 24 h. At the end of the incubation time, media was removed and cells were incubated in 10 μM of the fluorescent probe DHE, which detects intracellular •O₂– production (D’Agostino et al., 2007) in PBS for 30 min at 37 °C. Cells were washed in PBS and fixed using freshly prepared 4% paraformaldehyde. After fixation, cells were washed and stored in PBS at 4 °C for 3–5 days until fluorescent analysis was performed on a BioTek Synergy HT multi-mode microplate reader using 530 nm/590 nm excitation and emission filters.

4.8. MTT assay

The cytotoxic effects of all the test molecules used in this study were assessed on confluent monolayers of cells in 96 well plates using an MTT assay described previously (Watson et al., 2012). Absorbance values were corrected by protein content (determined using a BCA assay) and expressed as percentage viability compared to control untreated cells.

4.9. DDAH-1, eNOS and CAT-1 expression studies

To investigate the expression of eNOS and DDAH-1 in the hCMEC/D3s, SDS-PAGE and Western blotting (WB) were performed on whole cell lysates, prepared in TGN lysis buffer as described previously (Watson et al., 2012). Briefly, lysates were prepared from cells grown for 8 days in permeability medium and 30 μg of each lysate was loaded per well on a 10% SDS-PAGE gel. Following electrophoresis, proteins were transferred using semi-dry transfer onto methanol activated Immobilon-P PVDF membranes (0.45 μm pore size), blocked for 2 h at RT in PBS-Tween (PBS-T) with 5% milk powder and incubated overnight at 4 °C with goat anti-human DDAH-1 primary antibody at a dilution of 0.2 μg/ml PBS-T with 0.5% BSA, or Rabbit anti-human NOS III/eNOS primary antibody, used at a dilution of 1:2000 in PBS-T and 0.5% BSA. Membranes were then washed 3 × with PBS-T and incubated for 1 h at RT with rabbit anti-goat HRP conjugated secondary antibody was used at a dilution of 1:2500 in PBS-T with 0.5% BSA for chemiluminescence detection of DDAH-1 and goat anti-rabbit HRP conjugated secondary antibody was used at a dilution of 1:5000 in PBS-T with 0.5% BSA for chemiluminescence detection of eNOS. GAPDH was probed as a loading control using mouse anti-human primary antibody at 1:2000 in PBS-T with 0.5% BSA, and rabbit anti-mouse HRP conjugated secondary at 1:2000 in PBS-T with 0.5% BSA was used for chemiluminescence. For eNOS and DDAH-1 expression, and HUVEC whole cell lysate in RIPA buffer was used as a positive control (Murakami et al., 2006; Zhang et al., 2011).

The expression of CAT-1 was determined by SDS-PAGE, WB, and immunofluorescence (IF) with confocal microscopy. For SDS-PAGE and WB, the procedure above was used and immobilised proteins probed with rabbit anti-human CAT-1 primary antibody at a dilution of 1:250 in PBS-T and 0.5% BSA. Goat anti-rabbit HRP conjugated secondary antibody was used at a dilution of 1:5000 in PBS-T with 0.5% BSA for chemiluminescence detection of eNOS. For DDAH-1 and CAT-1 expression, and HUVEC whole cell lysate in RIPA buffer was used as a positive control (Abdelmagid et al., 2011).

IF of CAT-1 was performed on hCMEC/D3s grown on rat tail collagen type 1 coated sterile glass coverslips using a previously described protocol (Watson et al., 2012). Goat anti-rabbit Alexa Fluor 488 conjugated secondary antibody diluted at 1:200 in PBS was used to stain CAT-1 bound primary antibody used at a dilution of 1:200 in PBS-T overnight on the fixed hCMEC/D3s. 0.1 μg/ml DAPI was used to stain cell nuclei before mounting. Slides were viewed with a Zeiss LSM710 confocal microscope and image analysis software Zen 2009 at 63x (Zeiss, Germany).

4.10. Statistical analysis

Comparisons were made between control and test plates of cells and differences at p < 0.05 considered significant. Multiple-time accumulation data were analysed by Two Way Repeated Measures ANOVA tests and Holm-Sidak posthoc tests. MTT assay
and permeability assay data and ROS formation were compared to controls using One Way ANOVA and Bonferroni post-hoc tests. All data were analysed using Sigma Plot version 11.0 software (SPSS Science Software UK Ltd., Birmingham UK) and expressed as mean ± SEM.

Conflicts of interest

The authors acknowledge that there are no conflicts of interest.

Acknowledgements

The authors would like to thank Professor Pierre Couraud, Professor Babette Wekslr and Dr Ignacio Romero for the hCMEC/D3 cell line, Dr Miguel A. Lopez–Ramirez (Open University), Dr Egle Solito and Dr Enrico Cristante (Imperial College London) and for their help with the permeability assay. We would also like to thank Dr Jonathan Corcoran and Dr Maria de Castro Vasconcelos Goncalves (King’s College London) for their help with the confocal microscopy. An abstract of this work was presented at the 13th International Symposium on watching at the blood–Brain Barrier, Zurich, Switzerland, 2010: Watson, C., Pazarentzos, E., and S.A. Thomas (2010) Asymmetric dimethylarginine and the human blood–brain-barrier. This work was supported by The Wellcome Trust (080268), a BBSCR centre for integrative biomedical PhD studentship (BB/E527098/1) and a EPSRC DTA PhD studentship (EP503523/1).

References

Abdelmagid, S.A., Richard, J.A., Mcdonald, W.J., Thomas, L.N., Too, K.C., 2011. CAT–1-mediated arginine uptake and regulation of nitric oxide synthases for the survival of human breast cancer cell lines. J. Cell. Biochem. 112, 1084–1092.

Abbott, N.J., Ronnback, L., Hansson, E., 2006. Astrocyte–endothelial interactions at the blood–brain barrier. Nat. Rev. Neurosci. 7, 41–53.

Arlt, S., Schulze, F., Eichenlaub, M., Maas, R., Lemberg, J.T., Schwedhelm, E., Jahn, H., Boger, R.H., 2008. Asymmetrical dimethylarginine is increased in plasma and decreased in cerebral perfusion fluid of patients with Alzheimer’s disease. De- ment. Geriatr. Cogn. Disord. 26, 58–64.

Battisti, S., Valente, D., Albionici, L., Bei, R., Modesti, A., Palumbo, C., 2012. Nutritional stress and arginine autophagy confer high sensitivity to chloroquine toxicity in mesothelioma cells. Ann. J. Respir. Cell Mol. Biol. 46, 498–506.

Boger, R.H., 2003. The emerging role of asymmetrical dimethylarginine as a novel cardiovascular risk factor. Cardiovasc. Res. 59, 824–833.

Boger, R.H., 2004. Asymmetrical dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the “L-arginine paradox” and acts as a novel cardiovascular risk factor. J. Nutr. 134, 2842S–2847S.

Boger, R.H., Bode-Boger, S.M., Szuba, A., Tsa, P.S., Chan, J.R., Tanghao, O., Blaschke, T.F., Cooke, J.P., 1998. Asymmetrical dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolaemia. Circulation 98, 1842–1847.

Brouns, R., Marescau, B., Possenius, I., Searapipatjan, R., De Deyn, P.P., 2009. Di- methylarginine levels in cerebral fluid of hyperactive ischemic stroke patients are associated with stroke severity. Neurosci. Res. 34, 1642–1649.

Buhler, C.M., Lindeley, D.J., Couraud, P.O., Wsekler, B.B., Romero, I., Mowery, S.A., Knipp, G.T., 2010. ABC and SLC transporter expression and put substrate characterization across the human CMEC/D3 blood–brain barrier cell line. Mol. Pharm. 7, 1057–1068.

Cecchelli, R., Dehouck, B., Descamps, L., Fenart, L., Buee-Scherrer, V.V., Duhem, C., Brouns, R., Marescau, B., Possemiers, I., Sheorajpanday, R., De Deyn, P.P., 2009. Di- methylarginine–induced endothelial dysfunction in the cerebral circulation. Stroke 39, 180–184.

Dehouck, M.P., Jolliet-Riant, P., Bree, F., Fruchtart, J.C., Cecchelli, R., Tillement, J.P., 1992. Drug transfer across the blood–brain barrier: correlation between in vitro and in vivo models. J. Neurochem. 58, 1790–1797.

Dejana, E., Orensi, F., Langugnanli, M.C., 2008. The role of adherens junctions and VE-cadherin in the control of vascular permeability. J. Cell Sci. 121, 2115–2122.

Diaz-Perez, F., Radkojovic, C., Aguilera, V., Veas, C., Gonzalez, M., Lampert, L., Es- coveda, C., Aguayo, C., 2012. L-Arginine transport and nitric oxide synthesis in human endothelial progenitor cells. J. Cardiovasc. Pharm. 60, 439–449.

Fletcher, N.F., Wilson, G.K., Murray, J., Hu, K., Lewis, A., Reynolds, G.M., Stamataki, Z., Meredith, L.W., Rowe, I.A., Luo, G., Lopez-Ramirez, M.A., Baumert, T.F., Wekslr, B., Couraud, P.O., Kim, K.S., Romero, I.A., Jopling, C., Morgello, S., Balle, P., Mckeeing, J.A., 2011. Hepatitis C virus infects the endothelial cells of the blood–brain barrier. Gastroenterology.

Forster, C., Burek, M., Romero, I.A., Wekslr, B., Couraud, P.O., Drenckhahn, D., 2008. Differential effects of hydrocortisone and TNFalpha on tight junction proteins in an in vitro model of the human blood–brain barrier. J. Physiology 586, 1937–1949.

Forster, C., Jandi, N., Torondel, B., Murer-Rust, J., Malaki, M., O’Hara, P., Rossiter, S., Anthony, S., Madhani, M., Selwood, D., Smith, C., Wojciech-Stothard, B., Rudiger, A., Stidwill, R., Mcdonald, N.D.Q., Vannance, P., 2007. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat. Med. 13, 198–203.

Gross, E.J., Simon, A., Vekony, N., Rotmann, A., 2004. Plasma membrane transporters for arginine. J. Nutr. 134, 2752S–2759S, discussion 28535.

Kielstein, J.T., Donnerstag, F., Gasper, S., Menne, J., Kielstein, A., Martens-Loom- behoffer, J., Scaler, C., Cooke, J.P., Fliser, D., Bode-Boger, S.M., 2006. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 37, 2024–2029.

Kielstein, J.T., Kielstein, A., 2009. ADMA and the brain: an unfolding story. Am. J. Hypertens. 22, 240.

Kittel, A., Maas, R., 2014. Pharmacology and clinical pharmacology of methylargi- nines used as inhibitors of nitric oxide synthases. Curr. Pharm. Des. 20, 3530–3547.

Keswick, M., Keswick, K., Oleszczuk, J. 2014. The relation of maternal serum eNOS, NOSTRIN and ADMA levels with aetiology of preeclampsia and/or intrauterine fetal growth restriction. J. Matern. Fetal Neonatal. Med. 27, 452–457.

Keswick, M., Keswick, K., Oleszczuk, J. 2014. The relation of maternal serum eNOS, NOSTRIN and ADMA levels with aetiology of preeclampsia and/or intrauterine fetal growth restriction. J. Matern. Fetal Neonatal. Med. 27, 452–457.

Keswick, M., Keswick, K., Oleszczuk, J. 2014. The relation of maternal serum eNOS, NOSTRIN and ADMA levels with aetiology of preeclampsia and/or intrauterine fetal growth restriction. J. Matern. Fetal Neonatal. Med. 27, 452–457.
Palm, F., Oozato, M.L., Luo, Z., Wilcox, C.S., 2007. Dimethylarginine dimethylamino- nolohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am. J. Physiol. Heart Circ. Physiol. 293, H1227–H1245.
Patahendige, A., Skinner, R.A., Abbott, N.J., 2012. Establishment of a simplified in vitro porcine brain-brain barrier model with high transendothelial electrical resistance. Brain Res.
Perticone, F., Sciaccuca, A., Maio, R., Perticone, M., Maas, R., Boger, R.H., Tripepi, G., Sechi, G., Zoccali, C., 2005. Asymmetric dimethylarginine, L-arginine, and endo- thelial dysfunction in essential hypertension. J. Am. Coll. Cardiol. 46, 518–523.
Poller, B., Gutmann, H., Kranenbuhl, S., Weksiker, B., Romero, I., Couraud, P.O., Tuffin, G., Drewe, J., Huwyles, J., 2008. The human brain endothelial cell line hCMEC/D3 as a human blood-brain barrier model for drug transport studies. J. Neurochem. 107, 1358–1368.
Psychogios, N., hau, D.D., Peng, J., Guo, A.C., Mandal, R., Bosurta, S., Sinelnikov, I., Krishnamorthy, R., Eiener, R., Gautam, B., Young, N., Xia, J., Knox, C., Doug, L., Huang, P., Hollander, Z., Pedersen, T.L., Smith, S.R., Bamforth, F., Greiner, R., Mcmanus, B., Newmann, J.W., Goodfriend, T., Wishart, D.S., 2011. The human serum metabolome. PLoS One 6, e16957.
Rees, D.D., Paliner, R.M., Schulz, R., Hodson, H.F., Moncada, S., 1990. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br. J. Pharm. 101, 746–752.
Rotmann, A., Simon, A., Martine, U., Habermeier, A., Closs, E.L., 2007. Activation of classical protein kinase C decreases transport via systems y+ and y+L. Am. J. Physiol. Cell Physiol. 292, C2259–C2268.
Sanderson, L., Dogrue, M., Rodgers, J., Bradley, B., Thomas, S.A., 2008. The blood- brain barrier significantly limits effirontine entry into Trypanosoma brucei brucei infected mouse brain. J. Neurochem. 107, 1136–1146.
Sandoval, K.E., Wirt, K.A., 2008. Blood-brain barrier tight junction permeability and ischemic stroke. Neurobiol. Dis. 32, 200–219.
Scherbakov, N., Sandek, A., Martens-Lovenhoff, K., Kung, T., Turhan, G., Liman, T., Ebinger, M., V.O.N. Haehling, S., Bode-Boger, S.M., Endres, M., Doehner, W., 2012. Endothelial dysfunction of the peripheral vascular bed in the acute phase after ischemic stroke. Cereb. Dis. 33, 37–46.
Selley, M.L., 2003. Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer’s disease. Neurobiol. Aging 24, 903–907.
Sireen, M.P., Teerlink, T., Nijveldt, R.J., Prins, H.A., Richir, M.C., Leeuwen, P. A, V.A.N., Wanby, P., Teerlink, T., Bradström, L., Nilsson, I., Palmqvist, P., Carlson, M., 2006. Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population. Atherosclerosis 185, 271–277.
Watson, C.P., Dogrue, M., Mihooreoulu, L., Legley, D.J., Weksleri, B.B., Couraud, P.O., Romero, I.A., Thomas, S.A., 2012. The transport of nitfurinum, an anti-trypa- nosomal drug, in an in vitro model of the human blood-brain barrier: evidence for involvement of breast cancer resistance protein. Brain Res. 1436, 111–121.
Wekleri, B.B., Suhilea, E.A., Perrire, N., Chaneau, P., Holloway, K., Leveque, M., Tricoire-Leignel, H., Nicoc, A., Bourdoulous, S., Turowksi, P., Male, D.K., Roux, F., Greenwood, J., Romero, I.A., Courad, P.O., 2005. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J. 19, 1872–1874.
Wekleri, B.B., Romero, I.A., Courad, P.O., 2012. The hCMEC/D3 cell line as a model of the human blood-brain barrier. Fluids Barriers CNS 10, 16.
White, M.F., 1985. The transport of cationic amino acids across the plasma mem- brane of mammalian cells. Biochim. Biophys. Acta 822, 355–374.
Wojcik-Stothard, B., Torondel, B., Tsang, L.Y., Fleming, I., Fisslthaler, B., Leier, J.M., Vancle, P., 2007. The ADMA/DDAH pathway is a critical regulator of endo- thelial cell motility. J. Cell Sci. 120, 929–942.
Wojcik-Stothard, B., Torondel, B., Zhao, L., Renne, T., Leier, J.M., 2009. Modulation of Rac1 activity by ADMA/DDAH regulates pulmonary endothelial barrier function. Mol. Biol. Cell 20, 33–42.
Xiao, S., Wagner, L., Mahaney, J., Baylis, C., 2001. Uremic levels of urea inhibit L-arginine transport in cultured endothelial cells. Am. J. Physiol. Ren. Physiol. 280, F985–F995.
Yamawka, J., Kabashima, K., Kawanishi, M., Toda, K., Miyachi, Y., 2002. Cytotoxicity of IFN-gamma and TNF-alpha for vascular endothelial cell is mediated by nitric oxide. Biochem. Biophys. Res. Commun. 291, 780–786.
Yoo, J.H., Lee, S.C., 2001. Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis 158, 425–430.
Zhang, P., Hu, X., Xu, X., Chen, Y., Bache, R., 2011. Dimethylarginine dimethylami- nolohydrolase 1 modulates endothelial cell growth through nitric oxide and Akt. Arterioscler. Thromb. Vasc. Biol. 31, 890–897.
Zhang, P., Hu, X., Xu, X., Chen, Y., Bache, R., 2011. Dimethylarginine dimethylamin- ohydrolase 1 modulates endothelial cell growth through nitric oxide and Akt. Arterioscler. Thromb. Vasc. Biol. 31, 890–897.
Zhang, P., Hu, X., Xu, X., Chen, Y., Bache, R., 2011. Dimethylarginine dimethylami- nolohydrolase 1 modulates endothelial cell growth through nitric oxide and Akt. Arterioscler. Thromb. Vasc. Biol. 31, 890–897.
Zhang, P., Hu, X., Xu, X., Chen, Y., Bache, R., 2011. Dimethylarginine dimethylami- nolohydrolase 1 modulates endothelial cell growth through nitric oxide and Akt. Arterioscler. Thromb. Vasc. Biol. 31, 890–897.
Zhang, P., Hu, X., Xu, X., Chen, Y., Bache, R., 2011. Dimethylarginine dimethylami- nolohydrolase 1 modulates endothelial cell growth through nitric oxide and Akt. Arterioscler. Thromb. Vasc. Biol. 31, 890–897.
Zhang, P., Hu, X., Xu, X., Chen, Y., Bache, R., 2011. Dimethylarginine dimethylami- nolohydrolase 1 modulates endothelial cell growth through nitric oxide and Akt. Arterioscler. Thromb. Vasc. Biol. 31, 890–897.
Zhang, P., Hu, X., Xu, X., Chen, Y., Bache, R., 2011. Dimethylarginine dimethylami- nolohydrolase 1 modulates endothelial cell growth through nitric oxide and Akt. Arterioscler. Thromb. Vasc. Biol. 31, 890–897.
Zhang, P., Hu, X., Xu, X., Chen, Y., Bache, R., 2011. Dimethylarginine dimethylami- nolohydrolase 1 modulates endothelial cell growth through nitric oxide and Akt. Arterioscler. Thromb. Vasc. Biol. 31, 890–897.